Targeting gene expression to tumor cells with loss of wild-type p53 function

Cancer Gene Therapy

Volumn 7, Issue 1, 2000, Pages 4-12

  Zhu, Jingde ^a,b   Gao, Baomei ^a,c   Zhao, Jiangqin ^a   Balmain, Allan ^a,d  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b UNIVERSITY OF GLASGOW   (United Kingdom)

^c INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

p53; Transcription regulation; Tumor targeting

Indexed keywords

COMPLEMENTARY RNA; LUCIFERASE; PROTEIN P53;

APOPTOSIS; ARTICLE; BINDING SITE; CELL GROWTH; CONTROLLED STUDY; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; GENE TARGETING; GENE THERAPY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REPORTER GENE; REPRESSOR GENE; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE;

EID: 0033980572     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700091     Document Type: Article

References (51)

1. Verma IM, Somia N. Gene therapy: promises, problems, and prospects. Nature. 1997;389:239-242.
2. Vile RG, Sunassee K, Diaz RM. Strategies for achieving multiple layers of selectivity in gene therapy. Mol Med Today. 1998;2:84-92.
3. Miller N, Whelar J. Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Hum Gene Ther. 1997;8:803-815.
4. Kanai F, Lan KH, Shiratori Y, et al. In vivo gene therapy for α-fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of a cytosine deaminase gene. Cancer Res. 1997;57:461-465.
5. Richards CA, Austin EA, Huber BE. Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther. 1995;6:881-893.
6. Greenblatt MS, Bennett WP, Hollstein M, et al. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54:4855-4878.
7. Vile RG, Hart IR. In vitro and in vivo targeting of gene expression to melanoma cells. Cancer Res. 1993;53:962-967.
8. Harris C. Molecular epidemiology of human cancer: insights from the mutational analysis of the p53 tumour suppressor gene. Br J Cancer. 1996;73:261-269.
9. Hansen R, Oren M. p53, from inductive signal to cellular effect. Curr Opin Genet Dev. 1997;7:46-51.
10. Wang XW, Harris CC. TP53 tumor suppressor gene: clues to molecular carcinogenesis and cancer therapy. Cancer Surv. 1996;28:169-196.
11. 1 checkpoint after DNA damage. Mol Cell Biol. 1996;16: 1126-1137.
12. Knippschild U, Oren M, Deppert W. Abrogation of wild-type-p53 mediated growth-inhibition by nuclear exclusion. Oncogens. 1996;12:1755-1765.
13. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev. 1996;10:1054-1072.
14. Tsutsumi-Ishii Y, Tadokoro K, Hanaoka F, et al. Response of heat shock element within the human HSP70 promoter to mutated p53 genes. Cell Growth Differ. 1995;6:1-8.
15. Deuschle U, Meyer WKH, Thiesen HJ. Tetracycline-reversible silencing of eukaryotic promoters. Mol Cell Biol. 1995;15:1907-1914.
16. Shiio Y, Yamamoto T, Yamaguchi N. Identification of a DNA element that can enhance p53-mediated transactivation. Oncogene. 1993;8:2059-2065.
17. Nordeen SK. Luciferase reporter gene vectors for analysis of promoters and enhancers. Biotechniques. 1988;6:454-457.
18. Ciocca DR, Clark GM, Tandon AK, et al. Heat shock protein hsp70 in patients with axillary lymph-node negative breast cancer: prognostic implications. J Natl Cancer Inst. 1993;85:570-574.
19. Ciocca DR, Fuqua SA, Lock-Lim S, et al. Response of human breast cancer cells to heat shock and chemotherapeutic drugs. Cancer Res. 1992;52:3648-3654.
20. El-Deiry WS, Tokino T, Velculescu VE, et al. WAF1, a potential mediator of p53 tumor suppression. Cell. 1993; 75:817-825.
21. Barak Y, Yuven T, Haffner R, et al. mdm2 expression is induced by wild-type p53 activity. EMBO J. 1993;12:461-468.
22. Okamoto K, Beach D. Cyclin G is a transcriptional target of the p53 tumour suppressor protein. EMBO J. 1994;13: 4816-4822.
23. Kastan MB, Onyekwere O, Sidransky D, et al. Participation of p53 in the cellular response to DNA damage. Cancer Res. 1991;51:6304-6311.
24. Feinstein E, Gale RP, Reed J, et al. Expression of the normal p53 gene induces differentiation of K562 cells. Oncogene. 1992;7:1853-1857.
25. Neckers L, Whitesell L. Antisense technology: biological utility and practical considerations. Am J Physiol. 1993;265: L1-L12.
26. Syroid DE, Tapping RI, Capone JP. Regulated expression of a mammalian nonsense suppressor tRNA gene in vivo and in vitro using the lac operator/represser system. Mol Cell Biol. 1992;12:4271-4278.
27. El-Deiry WS, Kern SE, Pietenpol JA, et al. Definition of a consensus binding site for p53. Nat Genet. 1992;1:45-49.
28. Kern SE, Kinzler KW, Bruskin A. Identification of p53 as a sequence-specific DNA-binding protein. Science. 1991; 252:1707-1711.
29. Funk WD, Pak DT, Karas RH, et al. A transcriptionally active DNA-binding site for human p53 protein. Mol Cell Biol. 1992;12:2866-2871.
30. Hollstein MM, Shomer B, Greenblatt M. Somatic point mutations in the p53 gene of human tumors and cell lines: updated compilation. Nucleic Acids Res. 1996;24:141-146.
31. Cho Y, Gorina S, Jeffrey P, et al. Crystal structure of a p53 tumor suppressor-DNA complex: a framework for understanding how mutations inactivate p53. Science. 1994;265: 346-355.
32. Kern SE, Pietenpol JA, Thiagalingam S, et al. Oncogenic forms of p53 inhibit p53-regulated gene expression. Science. 1992;256:827-830.
33. Volgelstein B, Kinzler KW. p53 function and dysfunction. Cell. 1993;70:523-526.
34. Donehower LA, Bradley A. The tumour suppressor p53. Biochim Biophys Acta. 1993;1153:181-205.
35. Deb S, Jackson CT, Subler MA, et al. Modulation of cellular and viral promoters by mutant human p53 proteins found in tumour cells. J Virol. 1992;66:6164-6170.
36. Chin K-V, Ueda K, Pastan I, et al. Modulation of activity of the promoter of the human MDR1 gene by ras and p53. Science. 1992;255:460-462.
37. Wang Q, Zambetti GP, Suttle DP. Inhibition of DNA topoisomerase IIa gene expression by the p53 tumor suppressor. Mol Cell Biol. 1997;17:389-397.
38. Miyashita T, Harigai M, Hanada M, et al. Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res. 1994;54:3131-3135.
39. Seto E, Usheva A, Zambetti GP, et al. Wild-type p53 binds to the TATA-binding protein and represses transcription. Proc Natl Acad Sci USA. 1992;89:12028-12032.
40. Mack DH, Vattikar J, Pipas JM, et al. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type-p53. Nature. 1993;363:281-283.
41. Agoff SN, Hou JH, Linzer DIH, et al. Regulation of the human hsp70 promoter by p53. Science. 1993;259:84-87.
42. Ginsberg D, Mechta F, Yaniv M, et al. Wild-type p53 can down-modulate the activity of various promoters. Proc Natl Acad Sci USA. 1991;88:9979-9983.
43. Dittmer D, Pati S, Zambetti G, et al. Gain of function mutations in p53. Nat Genet. 1993;4:42-45.
44. Hsiao M, Low J, Dorn E, et al. Gain-of-function mutations of the p53 gene induce lymphohematopoietic metastatic potential and tissue invasiveness. Am J Pathol. 1994;145: 702-714.
45. Goyette MC, Cho K, Fashing CL, et al. Progression of colorectal cancer is associated with multiple tumor suppressor gene defects but inhibition of tumorigenicity is accomplished by correction of any single defect via chromosome transfer. Mol Cell Biol. 1992;12:1387-1395.
46. Takahashi T, Carbone D, Nau MM, et al. Wild-type but not mutant p53 suppresses the growth of human lung cancer cells bearing multiple genetic lesions. Cancer Res. 1992;52:2340-2343.
47. Roth JA, Cristiano RJ. Therapy for cancer: what have we done and where are we going? J Natl Cancer Inst. 1987;89: 21-39.
48. Nielsen LL, Maneval DC. p53 tumor suppressor gene therapy for cancer. Cancer Gene Ther. 1997;5:52-63.
49. Hupp TR, Sparks A, Lane DP. Small peptides activate the latent sequence-specific DNA binding function of p53. Cell. 1995;83:237-245.
50. Bischoff JR, Kirn DH, Williams A, et al. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science. 1996;274:373-376.
51. Boulikas T. Cancer gene therapy and immunotherapy. Int J Oncol. 1996;9:941-954.